Study of Activated Charcoal and Phosphate Binders in Adults with End Stage Renal Disease on Hemodialysis to Manage Mineral and Bone Disorder

What this Trial Is About

This research aims to evaluate the use of activated charcoal in managing hyperphosphatemia, a condition common in patients with end-stage renal disease ESRD who are on dialysis. Hyperphosphatemia can contribute to worsening vascular calcification, and current management mainly involves limiting dietary phosphorus and using phosphate binders. Activated charcoal, which is generally well tolerated, is being studied as a possible alternative to conventional phosphate binders in dialysis patients. Participants are randomly assigned to one of two groups one group receives standard care with calcium-based or non-calcium based phosphate binders such as sevelamer, while the other group receives these standard binders plus oral activated charcoal capsules taken with meals. The study is double-blinded and conducted over 8 weeks to assess the effect of activated charcoal on mineral and bone disorder related to chronic kidney disease. During the study, participants will have their serum phosphorus levels measured to evaluate treatment effects. Researchers will also track the percentage of patients who experience a significant decrease in itching intensity using a numerical rating scale. The study includes safety monitoring and aims to gather data on both efficacy and side effects. Overall participation duration includes screening, treatment, and follow-up during the 8-week trial period.

Activated Charcoal Use in Chronic Kidney Disease Patients